Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The data demonstrate that the company's next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, the company presented data showing durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The findings are significant because DMD is a severe genetic disorder characterized by progressive muscle degeneration, caused by nonsense mutations that introduce premature stop codons in the dystrophin gene. Current therapies offer limited benefits, and there is a critical need for treatments that restore full-length dystrophin. Tevard's sup-tRNA therapy aims to read through premature stop codons, allowing the production of native, full-length protein. In the presented studies, the sup-tRNAs achieved approximately 100% restoration of dystrophin levels in DMD models, which could potentially halt or reverse disease progression.
Similarly, truncating mutations in the TTN gene cause dilated cardiomyopathy, a leading cause of heart failure. Tevard's sup-tRNA approach provided durable rescue of full-length titin in mouse models and functional improvement in human cardiomyocytes. This suggests that the therapy could address the root cause of DCM-TTNtv, offering a novel treatment option for patients with limited alternatives.
Tevard's compact tRNA architecture enables flexible packaging into adeno-associated virus (AAV) vectors, allowing precise dose control and broad applicability for various nonsense mutations. The company is advancing programs in muscular dystrophies, heart disease, and neurological disorders. For more information, visit www.tevard.com. The full announcement, including downloadable images and bios, is available here.